An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Vinogradova, M., Gehling, V.S., Gustafson, A., Arora, S., Tindell, C.A., Wilson, C., Williamson, K.E., Guler, G.D., Gangurde, P., Manieri, W., Busby, J., Flynn, E.M., Lan, F., Kim, H.J., Odate, S., Cochran, A.G., Liu, Y., Wongchenko, M., Yang, Y., Cheung, T.K., Maile, T.M., Lau, T., Costa, M., Hegde, G.V., Jackson, E., Pitti, R., Arnott, D., Bailey, C., Bellon, S., Cummings, R.T., Albrecht, B.K., Harmange, J.C., Kiefer, J.R., Trojer, P., Classon, M.(2016) Nat Chem Biol 12: 531-538
- PubMed: 27214401 
- DOI: https://doi.org/10.1038/nchembio.2085
- Primary Citation of Related Structures:  
5CEH - PubMed Abstract: 
The KDM5 family of histone demethylases catalyzes the demethylation of histone H3 on lysine 4 (H3K4) and is required for the survival of drug-tolerant persister cancer cells (DTPs). Here we report the discovery and characterization of the specific KDM5 inhibitor CPI-455 ...